(Pedro L. Gonzalez, New York Post) Parents across the nation are facing a new threat to their children: the transgender-industrial complex. For different but sometimes overlapping reasons, the medical establishment, Big Pharma, the culture industry and government agencies are leading our kids on the road toward “transitioning” — whether parents like it or not.
For the private-economy actors, especially, the spread of gender ideology is a big boon to their bottom line.
To be sure, people experiencing gender dysphoria deserve compassionate care. But that’s very different from enabling minors in a vulnerable state of mind in these sexually confusing times to irreversibly alter their bodies with the latest in medical and pharmaceutical science.
Actually, that bit about the latest science isn’t quite right. Medroxyprogesterone acetate, a common drug in “gender-affirming therapy,” has long been used to chemically castrate sex offenders.
Another widely used medication is Lupron, a controversial hormone blocker. Lupron was initially developed to lower testosterone levels in men with prostate cancer, effectively chemically castrating them.
It’s now used as a puberty blocker in the booming business of “transitioning” children.
Lupron manufacturer AbbVie made $726 million on the drug alone in 2018. AbbVie has joined other major pharmaceutical companies in lobbying to keep drug prices high while virtue-signaling about diversity and inclusion.
Transgender people require lifelong medical support, making them ideal customers for the health-care industry, and the well-documented phenomenon of “peer contagion”—kids pressuring each other into thinking they’re all trans — ensures an endless supply of consumers.